Stock Ticker

  • Loading stock data...

Johnson & Johnson (NYSE:JNJ) And Actavis plc (NYSE:ACT) Cleared Of Painkillers Addiction Allegations

Johnson & Johnson (NYSE:JNJ) and Actavis plc (NYSE:ACT) have been cleared of any wrongdoing after being accused of not doing enough to warn patients of addiction risks posed by their prescription pain killers on sale. However, Purdue Pharma will have to make its case after a U.S District Court concluded it had a case to answer on the same issue.

City Can Appeal

U.S District Judge Jorge Alonso in Chicago in his final ruling concluded that the city did not prove enough that Johnson & Johnson (NYSE:JNJ) and Actavis plc (NYSE:ACT) caused damage as alleged. The city now has 30 days to file a new complaint while addressing issues rose in the final ruling.

Purdue was found to have made wrong statements about its Opioids drugs that mislead doctors and consumers. The state of Chicago has already received complaints amounting to 400,000 all related to Opioid prescriptions. The court sustained allegations of consumer fraud and false claims.

However, a bulk of claims about the drug was dismissed waiting to see the judge ruling on the merits of the case. There has been an ongoing talk that pharmaceuticals are not doing enough to protect patients from the potential risks associated with painkillers.

Rampant Pain Killers Abuse

Santa Clara and Orange counties have already sued a number of these companies for falsely portraying their drugs as rarely addictive yet they resulted in serious side effects. The wave of lawsuits against pharmaceutical company’s practices comes on the heels of reports that nearly 12 million people abuse painkillers annually.

The U.S. Centers for Disease Control and Prevention affirming that the misuse of drugs killed more people than heroin and cocaine in 2008, just highlights how the misuse of drugs remains a serious concern. The current lawsuits are intended to curtail pharmaceuticals practice on deceptive representations about the risks associated with particular drugs.

Published by Pamela Garcia

Pamela Garcia is a keen follower of U.S. stock market

Recent Stories

SignUp Now For Our Featured Newsletter